U.S. markets closed
  • S&P Futures

    4,136.50
    -17.00 (-0.41%)
     
  • Dow Futures

    32,990.00
    -165.00 (-0.50%)
     
  • Nasdaq Futures

    14,009.50
    -25.50 (-0.18%)
     
  • Russell 2000 Futures

    2,217.00
    -13.60 (-0.61%)
     
  • Crude Oil

    72.27
    +0.63 (+0.88%)
     
  • Gold

    1,774.70
    +5.70 (+0.32%)
     
  • Silver

    25.98
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1874
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3811
    +0.0002 (+0.02%)
     
  • USD/JPY

    110.0400
    -0.1100 (-0.10%)
     
  • BTC-USD

    35,131.07
    -316.86 (-0.89%)
     
  • CMC Crypto 200

    871.70
    -68.25 (-7.26%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    27,973.04
    -991.04 (-3.42%)
     

Top Ranked Value Stocks to Buy for December 7th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 7th:

Innoviva, Inc. (INVA): This pharmaceuticals company has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 24.3% over the last 60 days.

 

Innoviva, Inc. Price and Consensus

Innoviva, Inc. Price and Consensus
Innoviva, Inc. Price and Consensus

Innoviva, Inc. price-consensus-chart | Innoviva, Inc. Quote

 

Innoviva has a price-to-earnings ratio (P/E) of 4.78, compared with 14.80 for the industry. The company possesses a Value Score of A.

 

Innoviva, Inc. PE Ratio (TTM)

Innoviva, Inc. PE Ratio (TTM)
Innoviva, Inc. PE Ratio (TTM)

Innoviva, Inc. pe-ratio-ttm | Innoviva, Inc. Quote

 

Capital Product Partners L.P. (CPLP): This shipping company that provides marine transportation services has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 9.6% over the last 60 days.

 

Capital Product Partners L.P. Price and Consensus

Capital Product Partners L.P. Price and Consensus
Capital Product Partners L.P. Price and Consensus

Capital Product Partners L.P. price-consensus-chart | Capital Product Partners L.P. Quote

 

Capital Product Partners has a price-to-earnings ratio (P/E) of 4.67, compared with 9.40 for the industry. The company possesses a Value Score of A.

 

Capital Product Partners L.P. PE Ratio (TTM)

Capital Product Partners L.P. PE Ratio (TTM)
Capital Product Partners L.P. PE Ratio (TTM)

Capital Product Partners L.P. pe-ratio-ttm | Capital Product Partners L.P. Quote

 

360 DigiTech, Inc. (QFIN): This data driven, technology empowered digital platform has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 19% over the last 60 days.

 

360 DigiTech, Inc. Price and Consensus

360 DigiTech, Inc. Sponsored ADR Price and Consensus
360 DigiTech, Inc. Sponsored ADR Price and Consensus

360 DigiTech, Inc. price-consensus-chart | 360 DigiTech, Inc. Quote

 

360 DigiTech has a price-to-earnings ratio (P/E) of 3.56, compared with 30.00 for the industry. The company possesses a Value Score of A.

360 DigiTech, Inc. PE Ratio (TTM)

360 DigiTech, Inc. Sponsored ADR PE Ratio (TTM)
360 DigiTech, Inc. Sponsored ADR PE Ratio (TTM)

360 DigiTech, Inc. pe-ratio-ttm | 360 DigiTech, Inc. Quote

 

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
360 DigiTech, Inc. Sponsored ADR (QFIN) : Free Stock Analysis Report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
Capital Product Partners L.P. (CPLP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research